Renvela 800mg FC Tablets
PDF Leaflet Revision Date: 09 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Control of hyperphosphataemia in adult patients on dialysis or with CKD.
Dosage (summary)
Starting dose: 2.4 g to 4.8 g per day, taken three times daily with meals.
Special Populations
- Elderly population
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; not absorbed, minimal risk in breastfeeding.
Key Drug Interactions
- Ciprofloxacin
- Ciclosporin
- Mycophenolate mofetil
- Tacrolimus
- Levothyroxine
Contraindications
- Hypersensitivity to sevelamer
- Hypophosphataemia
- Bowel obstruction
Common side effects
- Nausea
- Vomiting
- Constipation
- Diarrhoea
- Fatigue
Counselling Points
- Take with meals
- Monitor phosphorus levels
- Assess swallowing ability
Serious warnings
- Serious gastrointestinal disorders
- Monitor for vitamin deficiencies
Important Disclaimer
The Renvela 800mg FC Tablets professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
